424792-57-4

Basic information

• Product Name: 1,2-DIFLUORO-4-(METHYLSULFONYL)BENZENE
• Synonyms: 1,2-Difluoro-4-(methylsulphonyl)benzene;3,4-Difluorophenyl methyl sulphone;3,4-Difluorophenyl Methyl Sulfone;EOS-60469;1,2-difluoro-4-methanesulfonyl-benzene
• CAS NO: 424792-57-4
• Molecular Formula: C₇H₆F₂O₂S
• Molecular Weight: 192.18
• Product Categories: blocks;BuildingBlocks;FluoroCompounds
• Mol File: 424792-57-4.mol

Chemical Properties

• Melting Point: 71°C
• Boiling Point: 302.4 °C at 760 mmHg
• Flash Point: 136.7 °C
• Appearance: /
• Density: 1.376 g/cm³
• Vapor Pressure: 0.00178mmHg at 25°C
• Refractive Index: 1.49
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 1,2-DIFLUORO-4-(METHYLSULFONYL)BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-DIFLUORO-4-(METHYLSULFONYL)BENZENE(424792-57-4)
• EPA Substance Registry System: 1,2-DIFLUORO-4-(METHYLSULFONYL)BENZENE(424792-57-4)

Safety Data

• Hazardous Substances Data: 424792-57-4(Hazardous Substances Data)

Usage

Uses

1,2-Difluoro-4-methylsulfonylbenzene

InChI:InChI=1/C7H6F2O2S/c1-12(10,11)5-2-3-6(8)7(9)4-5/h2-4H,1H3

Upstream product

• 367-11-3 ortho-difluorobenzene 
• 124-63-0 methanesulfonyl chloride 
• 130922-41-7 (3,4-difluorophenyl)(methyl)sulfane 
• 75-75-2 methanesulfonic acid 

Downstream Products

• 845616-10-6 1-(2-fluoro-4-methanesulfonyl-phenyl)-piperazine 
• 929212-99-7 bis(2-fluoro-4-methanesulfonyl-benzene)disulfide 
• 832714-48-4 (2-fluoro-4-(methylsulfonyl)phenyl)hydrazine 
• 20951-14-8 2-fluoro-1-methoxy-4-(methylsulfonyl)benzene 
• 1054521-30-0 (R)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyrrolidin-3-ol 
• 1054521-08-2 (S)-isopropyl 4-(5-(1-(2-fluoro-4-(methylsulfonyl)phenyl)pyrrolidin-3-yl)-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate 
• 1104452-50-7 4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one 
• 887453-50-1 1-(2-fluoro-4-methanesulfonylphenyl)piperidin-4-ol 
• 1259508-78-5 1-(2-fluoro-4-methanesulfonylphenyl)piperidin-4-one oxime 
• 1293319-33-1 C₂₁H₂₆FN₃O₆S 
• 1339944-38-5 tert-butyl 4-(5-chloro-1-(2-fluoro-4-(methylsulfonyl)-phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)piperidine-1-carboxylate 
• 1339944-43-2 5-chloro-1-(2-fluoro-4-(methylsulfonyl)phenyl)-4-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one 
• 1365998-48-6 (S)-tert-butyl 3-(2-fluoro-4-(methylsulfonyl)phenylamino)-2-oxo-1,4'-bipiperidin-1'-carboxylate 
• 1403681-74-2 C₁₅H₁₅FO₄S 

Relevant articles and documents

GPR119 Receptor Agonists

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

CRTH2 ANTAGONISTS

The following compounds are CRTH2 antagonists, useful in treatment of respiratory disease: [3-(2,4-dichlorophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(2-fluoro-4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methanesulfonyl-2-trifluoromethylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, (R)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, [3-(4-ethanesulfonylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, (S)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, ethanesulfonylaminobenzenesulfonyl)-6-fluoro-2-methyiindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(2-chloro-4-methanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(4-methanesulfonylbenzyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-chlorobenzyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-bromophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, and [3-(4-cyclopropylsulfamoylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid.

IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR

Compounds of formula (I) are CRTH2 antagonists, useful in the treatment of, for example, asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, and allergic rhinobronchitis. Formula (I) wherein R1, R2. R3 and R4 each independently are hydrogen, C1-C6alkyl, fully or partially fluorinated C1-C6alkyl, halo, -S(O)nR10, -SO2N(R10)2, -N(R10)2, -C(O)N(R10)2, -NR10C(O)R9, -CO2R10, -C(O)R9, -NO2, -CN or -OR11; wherein each R9 is independently C1-C6alkyl, aryl, heteroaryl; R10 is independently hydrogen, C1-C6alkyl, aryl, or heteroaryl; R11 is hydrogen, C1-C6alkyl, fully or partially fluorinated C1-C6alkyl or a group -SO2R10 ; n is 0, 1 or 2; R5 is C1-C6alkyl, fully or partially fluorinated C1-C6alkyl, C1-C6alkenyl, C1-C6alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; R6 is hydrogen, C1-C6alkyl or fully or partially fluorinated C1-C6alkyl ; R7 and R8 are independently hydrogen or C1-C6alkyl, or R7 and R8 together with the atom to which they are attached form a cycloalkyl group; and X is -CHR6-, -S(O)n-, -C(O)-, -NR6SO2- or -SO2NR6- wherein n is 0, 1 or 2.

SYNTHESIS OF METHYLSULPHONYL BENZENE COMPOUNDS

The present invention relates to a process for the synthesis of l-substituted-2-fluoro-4- methylsulfonylphenyl compounds.

BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME

Compounds of Formula: (I); wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substitut

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.